ArticleOncotarget2014
The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Review
- Epigenetic Regulation in Wilms Tumor.Biomedicines · 2025Review
- Inter-Ethnic Variations in the Clinical, Pathological, and Molecular Characteristics of Wilms Tumor.Cancers · 2024Review
- A rare case of extrarenal Wilms tumor of the uterine corpus: comprehensive genomic profile and review of the literature.Pathologica · 2023Review
- Article
- The potential key genes and pathways associated with Wilms tumor in quest of proper candidates for diagnostic and therapeutic purposes.Scientific reports · 2022Review
- Wilms tumour.Nature reviews. Disease primers · 2021Review
- Research advances in the targeted therapy and immunotherapy of Wilms tumor: a narrative review.Translational cancer research · 2021Review
- 11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood.Cancer · 2020Article
- Overgrowth Syndromes-Evaluation, Diagnosis, and Management.Frontiers in pediatrics · 2020Review
- Article
- miR-140-5p could suppress tumor proliferation and progression by targeting TGFBRI/SMAD2/3 and IGF-1R/AKT signaling pathways in Wilms' tumor.BMC cancer · 2019Article
- The genetic changes of Wilms tumour.Nature reviews. Nephrology · 2019Review
- Pharmacotherapeutic Management of Wilms Tumor: An Update.Paediatric drugs · 2019Review
- A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.Nature genetics · 2017Article
- Loss of heterozygosity on chromosome 16q increases relapse risk in Wilms' tumor: a meta-analysis.Oncotarget · 2017Article
- Bilateral Wilms tumour: a review of clinical and molecular features.Expert reviews in molecular medicine · 2017Review
- Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma.The Journal of biological chemistry · 2017Article
- Article
- RECK Gene Polymorphism is Associated with Susceptibility and Prognosis of Wilms' Tumor in Chinese Children.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
It is hypothesised that Wilms tumour (WT) results from aberrant renal development due to its embryonic morphology, associated undifferentiated precursor lesions (termed nephrogenic rests) and embryonic kidney-like chromatin and gene expression profiles. From the study of overgrowth syndrome-associated WT, germline dysregulation was identified in the imprinted region at 11p15 affecting imprinted genes IGF2 and H19. This is also detected in ~70% sporadic cases, making this the most common somatic molecular aberration in WT. This review summarises the critical discussion at an international workshop held under the auspices of The European Network for Cancer Research in Children and Adolescents (ENCCA) consortium, where the potential for drug development to target IGF2 and the WT epigenome was debated. Here, we consider current cancer treatments which include targeting the IGF pathway and the use of methylation agents alone or in combination with other drugs in clinical trials of paediatric cancers. Finally, we discuss the possibility of the use of these drugs to treat patients with WT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.